Bayer gets FDA priority review for blood cancer drug

German drugmaker Bayer won the U.S. Food and Drug Administration’s priority review status for an experimental drug for a difficult to treat type of blood cancer, bolstering its development pipeline.

Based on results of a Phase II study, the FDA plans to review Bayer’s copanlisib within six months instead of the usual 10 for use against follicular lymphoma which has returned or persisted despite at least two prior therapies, the company said in a statement on Wednesday.

Bayer, which is taking over U.S. seeds group Monsanto, is trying to follow up in its drug development efforts on the recent success of blood thinner Xarelto and anti-blindness treatment Eylea.

“Copanlisib may have a greater success and potential than we initially anticipated,” Bryan Garnier analysts said, adding they would revise their current peak sales estimate of 600 million euros ($666 million).

Bayer has said it was targeting peak annual sales of more than 500 million euros for the compound.

The Phase II trials has previously shown that copanlisib lead to the cancer receding in close to 60 percent of participants.

($1 = 0.9014 euros)

(Reporting by Ludwig Burger, editing by Louise Heavens)

Read More at Reuters

Get more stuff like this
in your inbox

Subscribe to our mailing list and get interesting stuff and updates to your email inbox.

Thank you for subscribing.

Something went wrong.

Got 10 Minutes? This Kettlebell Workout Only Has 3 Exercises
Screen kids and teens for obesity, U.S. experts say
How Your Sandwich Changed The World
Why You Should Move Your HIIT Workout to the Pool
Lena Dunham’s Trainer Tracy Anderson Says She Wanted to ‘Feel Better’ and Not Make Her Body ‘Look Different’
Ashley Graham Maintains Her Body Year-Round But Sometimes Still Feels Shy in a Bathing Suit
4 Ideas for Using Herbs You Probably Haven’t Thought Of
Bobbi Brown’s Top 10 Superfoods for Beauty and the Fun Way She Eats Them
5 Father’s Day Gift Ideas for Food-Loving Dads Everywhere
The Making Of Emotions, From Pleasurable Fear To Bittersweet Relief
4 Foolproof Tips to Make Healthy Veggie Chips at Home
A Food-Lover’s Mother’s Day Gift Guide
Here’s Why a Man Died After Swimming With a New Tattoo  
A MRSA Infection Cost Me $300,000—and Nearly Killed Me
Novartis heart drug success opens up new care option
Obamacare replacement bill to take center stage in Senate